JP2012524278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524278A5 JP2012524278A5 JP2012506186A JP2012506186A JP2012524278A5 JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5 JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- histone
- h3k18ac
- low
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 19
- 108010033040 Histones Proteins 0.000 claims 17
- 230000004048 modification Effects 0.000 claims 17
- 238000012986 modification Methods 0.000 claims 17
- 238000004393 prognosis Methods 0.000 claims 10
- 239000003734 thymidylate synthase inhibitor Substances 0.000 claims 10
- 230000004083 survival effect Effects 0.000 claims 9
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 7
- 229960002949 fluorouracil Drugs 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 5
- 102100039869 Histone H2B type F-S Human genes 0.000 claims 4
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 230000000052 comparative effect Effects 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 238000010186 staining Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 238000007619 statistical method Methods 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 238000003365 immunocytochemistry Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16921209P | 2009-04-14 | 2009-04-14 | |
| US16921609P | 2009-04-14 | 2009-04-14 | |
| US61/169,216 | 2009-04-14 | ||
| US61/169,212 | 2009-04-14 | ||
| US22516209P | 2009-07-13 | 2009-07-13 | |
| US61/225,162 | 2009-07-13 | ||
| PCT/US2010/031112 WO2010120942A2 (en) | 2009-04-14 | 2010-04-14 | Histone modification patterns for clinical diagnosis and prognosis of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012524278A JP2012524278A (ja) | 2012-10-11 |
| JP2012524278A5 true JP2012524278A5 (enExample) | 2013-06-13 |
Family
ID=42983132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506186A Pending JP2012524278A (ja) | 2009-04-14 | 2010-04-14 | がんの臨床診断および予後診断のためのヒストン修飾パターン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120094949A1 (enExample) |
| EP (1) | EP2419737A4 (enExample) |
| JP (1) | JP2012524278A (enExample) |
| CN (1) | CN102460173A (enExample) |
| AU (1) | AU2010236415A1 (enExample) |
| BR (1) | BRPI1013546A2 (enExample) |
| CA (1) | CA2758933A1 (enExample) |
| WO (1) | WO2010120942A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| WO2013084002A2 (en) * | 2011-12-07 | 2013-06-13 | Singapore Volition Pte Limited | Method for detecting nucleosome adducts |
| GB201303575D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
| GB201303576D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
| SG11201605259QA (en) * | 2013-12-30 | 2016-07-28 | Agency Science Tech & Res | Methods for measuring biomarkers in gastrointestinal cancer |
| JP2016044993A (ja) * | 2014-08-20 | 2016-04-04 | 有限会社マイテック | ヒストン化学修飾判定による癌診断方法 |
| CN107209190B (zh) * | 2014-10-29 | 2021-07-16 | 比利时意志有限责任公司 | 用于富集循环肿瘤dna的方法 |
| WO2016164392A1 (en) | 2015-04-06 | 2016-10-13 | The Johns Hopkins University | A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| US11015226B2 (en) * | 2015-10-06 | 2021-05-25 | Ontario Institute For Cancer Research (Oicr) | Targeting the histone pathway to detect and overcome anthracyclin resistance |
| GB201612815D0 (en) * | 2016-07-25 | 2016-09-07 | Belgian Volition Sa | Novel combination test |
| RU2765212C2 (ru) * | 2016-08-09 | 2022-01-26 | Б.Р.А.Х.М.С. Гмбх | Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии |
| CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110221072B (zh) * | 2019-06-10 | 2022-08-02 | 东南大学 | 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用 |
| CN112904006B (zh) * | 2021-01-28 | 2022-12-27 | 中山大学 | 一种乳腺癌预后预测分子标志物及其应用 |
| CN120712104A (zh) * | 2022-10-14 | 2025-09-26 | 广东天科雅生物医药科技有限公司 | 针对神经胶质瘤的肽疫苗及其用途 |
| WO2024233383A1 (en) * | 2023-05-05 | 2024-11-14 | University Of Utah Research Foundation | Systems and methods for point-of-care assessment based on pathology image analysis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| CA2607327A1 (en) * | 2005-04-29 | 2006-11-09 | The Regents Of The University Of California | Antibodies against histone modifications for clinical diagnosis and prognosis of cancer |
| EP1937837A2 (en) * | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
-
2010
- 2010-04-14 JP JP2012506186A patent/JP2012524278A/ja active Pending
- 2010-04-14 WO PCT/US2010/031112 patent/WO2010120942A2/en not_active Ceased
- 2010-04-14 CA CA2758933A patent/CA2758933A1/en not_active Abandoned
- 2010-04-14 BR BRPI1013546-4A patent/BRPI1013546A2/pt not_active IP Right Cessation
- 2010-04-14 CN CN2010800251368A patent/CN102460173A/zh active Pending
- 2010-04-14 EP EP10765132A patent/EP2419737A4/en not_active Withdrawn
- 2010-04-14 AU AU2010236415A patent/AU2010236415A1/en not_active Abandoned
- 2010-04-14 US US13/262,219 patent/US20120094949A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524278A5 (enExample) | ||
| Zhou et al. | Increased expression of long-noncoding RNA ZFAS1 is associated with epithelial-mesenchymal transition of gastric cancer | |
| Khan et al. | Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer | |
| Mehan et al. | Validation of a blood protein signature for non-small cell lung cancer | |
| Chen et al. | Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma | |
| Maráz et al. | Thrombocytosis has a negative prognostic value in lung cancer | |
| Zhao et al. | Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma | |
| Carr et al. | Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro | |
| Chen et al. | Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint | |
| She et al. | C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma | |
| Tan et al. | Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients | |
| Lu et al. | Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival | |
| Fiala et al. | High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib | |
| Zhang et al. | The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non‐small cell lung cancer after surgery | |
| Kuiper et al. | VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib | |
| Dabner et al. | Merkel cell Polyomavirus and p63 status in Merkel cell carcinoma by immunohistocnemistry: Merkel cell Polyomavirus positivity is inversely correlated with sun damage, but neither is correlated with outcome | |
| Qiu et al. | Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells | |
| Ge et al. | Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma | |
| Munoz-Colmenero et al. | Plasma tumor M2-pyruvate kinase levels in different cancer types | |
| Jouhi et al. | The expression of Toll-like receptors 2, 4, 5, 7 and 9 in Merkel cell carcinoma | |
| Yan et al. | Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients | |
| Hu et al. | Noninvasive diagnosis of nasopharyngeal carcinoma based on phenotypic profiling of viral and tumor markers on plasma extracellular vesicles | |
| JP2017505897A5 (enExample) | ||
| Zhao et al. | Quantitative proteomic analysis of optimal cutting temperature (OCT) embedded core-needle biopsy of lung cancer | |
| Bianchi et al. | Circulating microRNAs: next-generation biomarkers for early lung cancer detection |